Date of Award


Degree Type

Selective Evidence-Based Medicine Review

Degree Name

Master of Science in Health Sciences - Physician Assistant


Physician Assistant Studies

Department Chair

John Cavenagh, MBA, PhD, PA-C


OBJECTIVE: The objective of this selective EBM review is to determine whether or not botulinum toxin A is an effective treatment for children who have lower limb spasticity from cerebral palsy.

STUDY DESIGN: The study by Carraro et al was a randomized double-blind clinical trial done in 2015.6The study done by Kim et al was a randomized, double-blind controlled clinical trial done in 2010.7 The study by Py et al was a clinical trial done in 2005-2006.8

DATA SOURCES: Data sources obtained for this review were articles published in peerreviewed journals found using PubMed Database.

OUTCOMES MEASURED: The outcome measured the effectiveness of Botox and Botox verse Xeomin and Neuronox, as well as the improvement of Gross Motor function with the use of Botox and Neuronox.

RESULTS: The study Carraro et al showed that incobotulinum toxin A (Xeomin) was just as effective for the treatment of spasticity from cerebral palsy, as onabotulinum toxin A (Botox).6The study by Kim et al, showed the Neuronox was just as effective as Botox.7Lastly, the study by Py et al, provided clear evidence that onabotulinum toxin A (Botox), was an effective treatment of spastic gait in cerebral palsy in the first place.8

CONCLUSIONS: The results of the studies showed at Xeomin, Neuronox, and Botox all have similar results efficacy for the treatment of lower limb spasticity in children with cerebral palsy.